Pages that link to "Q84661349"

The following pages link to Determinants of serum sclerostin in healthy pre- and postmenopausal women (Q84661349):

Displaying 49 items.

• Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort (Q30990351) (← links)
• Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort (Q31038073) (← links)
• Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis (Q33835723) (← links)
• The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes (Q33905129) (← links)
• Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. (Q34206461) (← links)
• Elevated circulating Sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. (Q34396458) (← links)
• The convergence of fracture repair and stem cells: interplay of genes, aging, environmental factors and disease (Q35683050) (← links)
• Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone. (Q36031246) (← links)
• Circulating sclerostin is elevated in short-term and reduced in long-term SCI. (Q36143807) (← links)
• Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls (Q36143916) (← links)
• Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels. (Q36510250) (← links)
• Sclerostin serum levels in patients with systemic autoimmune diseases (Q36561360) (← links)
• Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels (Q36561855) (← links)
• Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? (Q36633205) (← links)
• Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry (Q36685956) (← links)
• Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice (Q36737118) (← links)
• Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes (Q37086296) (← links)
• Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans (Q37423382) (← links)
• Clinical utility of serum sclerostin measurements (Q37605570) (← links)
• Relative influence of heritability, environment and genetics on serum sclerostin (Q37627846) (← links)
• Effect of supplemental vitamin D and calcium on serum sclerostin levels (Q37682879) (← links)
• Bone turnover markers: use in osteoporosis (Q38016073) (← links)
• Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches (Q38128460) (← links)
• The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis. (Q38184470) (← links)
• Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis (Q38920636) (← links)
• The Utility of Biomarkers in Osteoporosis Management. (Q38921875) (← links)
• Hormonal and systemic regulation of sclerostin (Q39037907) (← links)
• Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths (Q41537603) (← links)
• Serum sclerostin levels in healthy men over 50 years of age. (Q44705606) (← links)
• Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. (Q45268599) (← links)
• Increased sclerostin and bone turnover after diet-induced weight loss in type 2 diabetes: a post hoc analysis of the MADIAB trial (Q47255490) (← links)
• MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis (Q47428797) (← links)
• Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study. (Q48762542) (← links)
• Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats (Q51124369) (← links)
• Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome. (Q51345508) (← links)
• Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder. (Q52316128) (← links)
• High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study. (Q55072999) (← links)
• Vascular calcification and renal bone disorders (Q59100578) (← links)
• Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine (Q85289560) (← links)
• Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis (Q85673892) (← links)
• Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls (Q87238504) (← links)
• Sclerostin and parathyroid hormone responses to acute whole-body vibration and resistance exercise in young women (Q89338582) (← links)
• Sclerostin and Its Associations With Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents (Q89967626) (← links)
• Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review (Q90406658) (← links)
• Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures (Q90616784) (← links)
• Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients (Q90747662) (← links)
• Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study (Q91964524) (← links)
• Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients (Q92277957) (← links)
• Low Serum Levels of DKK2 Predict Incident Low-Impact Fracture in Older Women (Q92358423) (← links)